Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

David A. Hyman, MD, JD, on Inclusive Shared Savings

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Welcome and Introduction to Vi3C

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




May
04
Today In Oncology
USPSTF Issues Final Recommendation Statement on Screening for Breast Cancer
Relapsed or Refractory CD7-Positive Leukemia or Lymphoma CAR T-Cell Therapy Plus HSCT Without GVHD Prophylaxis
Premastectomy Radiotherapy, Surgery, and Immediate Breast Reconstruction
Liposomal Irinotecan vs Topotecan in Relapsed Small Cell Lung Cancer
Smoking Cessation Regimens: Does Dose of Therapy Matter?
View More 
Advertisement
© 2024 HSP News Service, L.L.C.
Designed by Harborside